Social mobility and healthy behaviours from a gender perspective in the Spanish multicase-control study (MCC-Spain).


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 21 01 2021
accepted: 26 04 2021
entrez: 12 5 2021
pubmed: 13 5 2021
medline: 21 10 2021
Statut: epublish

Résumé

There is evidence for the influence of socioeconomic status (SES) on healthy behaviours but the effect of social mobility (SM) is not yet well known. This study aims to analyse the influence of origin and destination SES (O-SES and D-SES) and SM on healthy behaviours and co-occurrence, from an integrated gender and age perspective. Data were obtained from the controls of MCC-Spain between 2008-2013 (3,606 participants). Healthy behaviours considered: healthy diet, moderate alcohol consumption, non-smoking and physical activity. SM was categorized as stable high, upward, stable medium, downward or stable low. Binary and multinomial logistic regression models were adjusted. Those aged <65, with a low O-SES, D-SES and stable low SM are less likely to have healthy behaviours in the case of both women (physically active: OR = 0.65 CI = 0.45-0.94, OR = 0.71 CI = 0.52-0.98, OR = 0.61 CI = 0.41-0.91) and men (non-smokers: OR = 0.44 CI = 0.26-0.76, OR = 0.54 CI = 0.35-0.83, OR = 0.41 CI 0.24-0.72; physically active: OR = 0.57 CI = 0.35-0.92, OR = 0.64 CI = 0.44-0.95, OR = 0.53 CI = 0.23-0.87). However, for those aged ≥65, this probability is higher in women with a low O-SES and D-SES (non-smoker: OR = 8.09 CI = 4.18-15.67, OR = 4.14 CI = 2.28-7.52; moderate alcohol consumption: OR = 3.00 CI = 1.45-6.24, OR = 2.83 CI = 1.49-5.37) and in men with a stable low SM (physically active: OR = 1.52 CI = 1.02-1.26). In the case of men, the same behaviour pattern is observed in those with a low O-SES as those with upward mobility, with a higher probability of co-occurring behaviours (three-to-four behaviours: OR = 2.00 CI = 1.22-3.29; OR = 3.13 CI = 1.31-7.48). The relationship of O-SES, D-SES and SM with healthy behaviours is complex and differs according to age and gender.

Identifiants

pubmed: 33979362
doi: 10.1371/journal.pone.0251447
pii: PONE-D-21-02188
pmc: PMC8115806
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0251447

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Rev Esp Salud Publica. 2004 Jul-Aug;78(4):493-504
pubmed: 15384263
Nutr Metab Cardiovasc Dis. 2016 Dec;26(12):1057-1063
pubmed: 27524802
Int J Epidemiol. 2008 Dec;37(6):1367-74
pubmed: 18550623
Soc Sci Med. 2000 May;50(10):1385-401
pubmed: 10741575
Gac Sanit. 2013 May-Jun;27(3):263-72
pubmed: 23394892
Prev Med Rep. 2018 Jul 23;12:1-5
pubmed: 30116703
Drug Alcohol Depend. 2015 Nov 1;156:1-13
pubmed: 26371405
Rev Saude Publica. 2018;52:47
pubmed: 29723387
Trials. 2019 Feb 28;20(1):151
pubmed: 30819224
Prev Med. 2011 Jun;52(6):434-8
pubmed: 21421001
Lancet. 2012 Sep 15;380(9846):1011-29
pubmed: 22964159
Int J Epidemiol. 1993 Jun;22(3):512-9
pubmed: 8359969
Prev Med. 2016 Dec;93:64-69
pubmed: 27663427
J Epidemiol Community Health. 2017 Jul;71(7):673-680
pubmed: 27979970
BMC Public Health. 2016 Jul 29;16:657
pubmed: 27473458
Rev Esp Salud Publica. 2001 Jan-Feb;75(1):13-22
pubmed: 11400411
Gac Sanit. 2015 Jul-Aug;29(4):308-15
pubmed: 25613680
Prev Chronic Dis. 2019 Jun 13;16:E74
pubmed: 31198164
Soc Sci Med. 2015 Oct;142:241-8
pubmed: 26318213
Tob Control. 2016 May;25(3):295-300
pubmed: 25701858
Med Sci Sports Exerc. 2011 Jul;43(7):1334-59
pubmed: 21694556
Eur J Public Health. 2014 Apr;24(2):199-204
pubmed: 23748597
Soc Sci Med. 2009 Jun;68(12):2206-14
pubmed: 19394742
Int J Equity Health. 2017 Jan 3;16(1):1
pubmed: 28057005
Am Heart J. 2012 Jun;163(6):1037-40
pubmed: 22709758
Biomedica. 2014 Jul-Sep;34(3):447-59
pubmed: 25504131
Exp Ther Med. 2016 Oct;12(4):2657-2664
pubmed: 27703514
BMC Public Health. 2017 May 23;17(1):497
pubmed: 28535751
Public Health. 2020 Apr;181:94-101
pubmed: 31981813
Tob Use Insights. 2017 Aug 14;10:1179173X17726297
pubmed: 28839446
Gac Sanit. 2004 May;18 Suppl 1:2-6
pubmed: 15171850
PLoS One. 2018 Feb 14;13(2):e0191855
pubmed: 29444095

Auteurs

M Pinto-Carbó (M)

Cancer and Public Health Area, Foundation for the Promotion of the Research in Healthcare and Biomedicine (FISABIO-Salud Pública), Valencia, Valencian Community, Spain.

R Peiró-Pérez (R)

Inequalities Area, Foundation for the Promotion of the Research in Healthcare and Biomedicine (FISABIO-Salud Pública), Valencia, Valencian Community, Spain.
General Directorate of Public Health, Valencia, Valencian Community, Spain.
Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.

A Molina-Barceló (A)

Cancer and Public Health Area, Foundation for the Promotion of the Research in Healthcare and Biomedicine (FISABIO-Salud Pública), Valencia, Valencian Community, Spain.

M Vanaclocha-Espi (M)

Cancer and Public Health Area, Foundation for the Promotion of the Research in Healthcare and Biomedicine (FISABIO-Salud Pública), Valencia, Valencian Community, Spain.

J Alguacil (J)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Centre for Health and Environmental Research, Huelva University, Huelva, Andalucia, Spain.

G Castaño-Vinyals (G)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Barcelona Institute for Global Health (ISGlobal), Barcelona, Catalonia, Spain.
Universitat Pompeu Fabra, Plaça de la Mercè, Barcelona, Catalonia, Spain.
Hospital del Mar Medical Research Institute, Barcelona, Catalonia, Spain.

C O'Callaghan-Gordo (C)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Barcelona Institute for Global Health (ISGlobal), Barcelona, Catalonia, Spain.
Universitat Pompeu Fabra, Plaça de la Mercè, Barcelona, Catalonia, Spain.
Faculty of Health Science,Universitat Oberta de Catalunya, Barcelona, Catalonia, Spain.

E Gràcia-Lavedan (E)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Barcelona Institute for Global Health (ISGlobal), Barcelona, Catalonia, Spain.
Hospital del Mar Medical Research Institute, Barcelona, Catalonia, Spain.

B Pérez-Gómez (B)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.

V Lope (V)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.

N Aragonés (N)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain.

A J Molina (AJ)

The Research Group in Gene-Environment and Health Interactions, Institute of Biomedicine (IBIOMED), University of León, León, Castilla y León, Spain.

T Fernández-Villa (T)

The Research Group in Gene-Environment and Health Interactions, Institute of Biomedicine (IBIOMED), University of León, León, Castilla y León, Spain.

L Gil-Majuelo (L)

Ministry of Health of the Basque Government, Sub-Directorate for Public Health and Addictions of Gipuzkoa, San Sebastián, Gipuzkoa, Spain.
Biodonostia Health Research Institute, Group of Epidemiology of Chronic and Communicable Diseases, San Sebastián, Gipuzkoa, Spain.

P Amiano (P)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Ministry of Health of the Basque Government, Sub-Directorate for Public Health and Addictions of Gipuzkoa, San Sebastián, Gipuzkoa, Spain.
Biodonostia Health Research Institute, Group of Epidemiology of Chronic and Communicable Diseases, San Sebastián, Gipuzkoa, Spain.

T Dierssen-Sotos (T)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Cantabria University, Santander, Cantabria, Spain.

I Gómez-Acebo (I)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Cantabria University, Santander, Cantabria, Spain.

M Guevara (M)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Navarra Public Health Institute, Pamplona, Navarra, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Navarra, Spain.

C Moreno-Iribas (C)

Navarra Public Health Institute, Pamplona, Navarra, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Navarra, Spain.

M Obón-Santacana (M)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), Barcelona, Catalonia, Spain.
ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.

M M Rodríguez-Suárez (MM)

Preventive Medicine and Public Health Area, Oviedo University, Oviedo, Asturias, Spain.
Central University Hospital of Asturias, Public Health Service of the Principe de Asturias, Oviedo, Asturias, Spain.

I Salcedo-Bellido (I)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Andalucia, Spain.
Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, Andalucia, Spain.

A Delgado-Parrilla (A)

Centre for Health and Environmental Research, Huelva University, Huelva, Andalucia, Spain.

R Marcos-Gragera (R)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona, Catalonia, Spain.
Descriptive Epidemiology, Genetics and Cancer Prevention Group [Girona Biomedical Research Institute], Girona, Catalonia, Spain.

M D Chirlaque (MD)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, El Palmar, Murcia, Spain.

M Kogevinas (M)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Barcelona Institute for Global Health (ISGlobal), Barcelona, Catalonia, Spain.
Universitat Pompeu Fabra, Plaça de la Mercè, Barcelona, Catalonia, Spain.
Hospital del Mar Medical Research Institute, Barcelona, Catalonia, Spain.

M Pollán (M)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.
Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.

D Salas (D)

Cancer and Public Health Area, Foundation for the Promotion of the Research in Healthcare and Biomedicine (FISABIO-Salud Pública), Valencia, Valencian Community, Spain.
General Directorate of Public Health, Valencia, Valencian Community, Spain.
Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH